BioCentury | Feb 13, 2020

Vivo-led $105M round to spur development of ALX’s CD47

Encouraged by safety data for ALX’s CD47-targeted cancer therapy, Vivo Capital led the biotech’s $105 million series C Wednesday to fuel its clinical catch-up to its most advanced competitor. Other new investors including funds managed...
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

The rush to drug CD47 shows no signs of abating, with five companies launching clinical programs for cancer this year and three moving forward on the back of encouraging Phase I data. The differentiator may...
BC Week In Review | Dec 8, 2017
Clinical News

Alexo reports preliminary Phase I data for ALX148 in solid tumors and lymphoma

In November, Alexo Therapeutics Ltd. (Dublin, Ireland) reported preliminary data from 17 patients with advanced solid tumors and lymphoma in a Phase I trial showing that IV ALX148 was well tolerated with 1 treatment-related serious...
BC Innovations | Dec 5, 2017
Distillery Therapeutics


INDICATION: Pancreatic cancer; melanoma Cell culture and mouse studies suggest inhibiting MHCI, MHCI components or the macrophage MHC1 binding partner LILRB1 could help treat pancreatic cancer and melanoma. In co-culture of human pancreatic neuroendocrine tumor...
BC Week In Review | Dec 1, 2017
Clinical News

Alexo reports Phase I data for its CD47 inhibitor

Alexo Therapeutics Ltd. (Dublin, Ireland) reported data from 17 patients with advanced solid tumors and lymphoma in the single-agent portion of an open-label, dose-escalation Phase I trial showing that 0.3-30 mg/kg doses of ALX148 monotherapy...
BC Week In Review | Apr 14, 2017
Clinical News

ALX148: Ph I AT148001 started

Alexo began the 2-part, open-label, dose-escalation, U.S. Phase I AT148001 trial to evaluate ALX148 in about 110 patients. Part 1 will evaluate ascending doses of ALX148 given alone weekly or every 2 weeks. Part 2...
BC Innovations | Aug 25, 2016
Targets & Mechanisms

Forty Seven and counting

With companies lining up to block CD47 for cancer, the cell surface protein is emerging as one of the top new targets in oncology. But the list of suitors could be about to get a...
BioCentury | Jul 25, 2016
Emerging Company Profile

Targeted phagocytosis

Alexo Therapeutics Inc. is developing variants of signal regulatory protein alpha that antagonize CD47 to increase macrophage phagocytosis induced by anticancer antibodies. Using the variants alongside antibody therapeutics could avoid on-target phagocytosis of healthy cells...
Items per page:
1 - 8 of 8